Liang Xu

Dr. Liang Xu


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2020 in Trials
Verified
Journal Article
Open access
PDF file
ZWZong-Yu Wang
Zong-Yu Wang
SFShou-Zhi Fu
Shou-Zhi Fu
LXLiang Xu
Liang Xu
SLShusheng Li
Shusheng Li
KQKejian Qian
Kejian Qian
PMPeng-Lin Ma
Peng-Lin Ma
Objectives: This study aims to determine the protection provided by Shenfu injection (a traditional Chinese medicine) against development of organ dysfunction in critically ill patients with coronavirus disease 2019 (COVID-19). Trial design: This study is a multicenter, randomized, controlled, open-label, two-arm ratio 1:1, parallel group clinical trial. Participants: The patients, who are aged from 18 to 75 years old, with a confirmed or suspected diagnosis of severe or critical COVID-19, will be consecutively recruited in the study, according to the guideline on diagnosis and treatment of COVID-19 (the 7th version) issued by National Health Commission of the People’s Republic of China. Exclusion criteria include pregnant and breastfeeding women, atopy or allergies to Shenfu Injection (SFI), severe underlying disease (malignant tumor with multiple metastases, uncontrolled hemopathy, cachexia, severe malnutrition, HIV), active bleeding, obstructive pneumonia caused by lung tumor, severe pulmonary interstitial fibrosis, alveolar proteinosis and allergic alveolitis, continuous use of immunosuppressive drugs in last 6 months, organ transplantation, expected death within 48 hours, the patients considered unsuitable for this study by researchers. The study is conducted in 11 ICUs of designated hospitals for COVID-19, located in 5 cities of China. Intervention and comparator: The enrolled patients will randomly receive 100 ml SFI (study group) or identical volume of saline (control group) twice a day for seven consecutive days. Patients in the both groups will be given usual care and the necessary supportive therapies as recommended by the latest edition of the management guidelines for COVID-19 (the 7th version so far). Main outcomes: The primary endpoint is a composite of newly developed or exacerbated organ dysfunction. This is defined as an increase in the sequential organ failure assessment (SOFA) score of two or more, indicating sepsis and involvement of at least one organ. The SOFA score will be measured for the 14 days after enrolment from the baseline (the score at randomization). The secondary endpoints are shown below: • SOFA score in total • Pneumonia severity index score • Dosage of vasoactive drugs • Ventilation free days within 28 days • Length of stay in intensive care unit • Total hospital costs to treat the patient • 28-day mortality • The incidence of adverse drug events related to SFI Randomisation: The block randomization codes were generated by SAS V.9.1 for allocation of participants in this study. The ratio of random distribution is 1:1. The sealed envelope method is used for allocation concealment. Blinding (masking): The patients and statistical personnel analyzing study data are both blinded. The blinding of group assignment is not adopted for the medical staff. Numbers to be randomised (sample size): This study is expected to recruit 300 patients with COVID-19, (150 in each group). Trial Status: Protocol version 2.0, February 15, 2020. Patient recruitment started on February 25, and will end on August 31, 2020. Trial registration: Chinese Clinical Trial Registry: ChiCTR2000030043. Registered February 21, 2020, http://www.chictr.org.cn/showprojen.aspx?proj=49866 Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.

10 July 2020 in Medicine
Verified
Journal Article
Open access
LMLi Ma
Li Ma
WDWenqin Dai
Wenqin Dai
YLYongbo Lin
Yongbo Lin
ZZZhongyuan Zhang
Zhongyuan Zhang
YPYunhong Pan
Yunhong Pan
LXLiang Xu
Liang Xu
Objective: This study was designed to investigate the effects of leukocyte Rho kinase activity and serum Cystatin C (Cys C) on cardiovascular events in patients with acute coronary syndrome (ACS).Methods: A total of 48 patients with ST-segment elevation myocardial infarction (STEMI), 23 patients with non-ST-segment elevation myocardial infarction (NSTEMI), 25 patients with unstable angina (UA) and 20 patients with no-acute coronary syndrome as control from January 2017 to June 2018 in Tianyou Hospital affiliated to Wuhan University of Science and Technology were selected in this study. Western blot was used to detect the leukocyte Rho kinase activity and Elisa kit was used to measure serum Cys C. Univariate and multivariate analysis were used to analyze the influencing factors of cardiovascular events in ACS patients.Results: The activity of leukocyte Rho kinase and serum Cys C were gradually reduced in the STEMI, NSTEMI and UA patients, but all significantly higher than that in No-ASC patients, and there was a positive correlation between leukocyte Rho kinase activity and serum Cys C in ACS patients (r = 0.516,P < .001). The activity of leukocyte Rho kinase was positively correlated with the levels of serum TNF-α (r = 0.634,P < .001), IL-6 (r = 0.578,P < .001), IL-8 (r = 0.582,P < .001) in ACS patients, and the level of Cys C was positively correlated with the levels of serum TNF-α (r = 0.634,P < .001), IL-6 (r = 0.578,P < .001), IL-8 (r = 0.582,P < .001) in ACS patients. Univariate and multivariate analysis showed that the leukocyte Rho kinase activity (HR = 2.994, 95%CI = 1.328–6.054,P < .0001) and the levels of serum Cys C (HR = 1.692, 95%CI = 1.028–2.124,P < .0001) were independent influencing factors of cardiovascular events in ACS patients.Conclusion: The leukocyte Rho kinase activity and serum Cystatin C are high in acute coronary syndrome patients, and are the independent influencing factors of cardiovascular events in ACS patients.

2 September 2023 in Journal of Surgical Research
Verified
Journal Article
Closed access
YLYongbo Lin
Yongbo Lin
LMLi Ma
Li Ma
HDHanliang Dan
Hanliang Dan
GCGang Chen
Gang Chen
JDJian Dai
Jian Dai
YLYuqi Liu
Yuqi Liu

1 November 2024 in Allergologia et Immunopathologia
Verified
Journal Article
Open access
PDF file
LMLi Ma
Li Ma
LCLiping Cai
Liping Cai
JPJiayue Pan
Jiayue Pan
ZCZimin Cheng
Zimin Cheng
YLYuanyuan Lv
Yuanyuan Lv
LXLiang Xu
Liang Xu
In coronary microembolization, inflammatory cell infiltration, patchy necrosis, and extensive intra-myocardial hemorrhage are dominant, which induce myocardial dysfunction with clinical symptoms of chronic ischemic cardiomyopathy. Microembolization can lead to obstruction of the coronary microvessels and result in the micro-infarction of the heart. The inflammation and elevated expression of the tumor necrosis factor in cardiomyocytes and the activation of extracellular ERK are involved in initiating the inflammatory response mechanism. The PI3K/Akt signaling pathway is the enriched pathway, and for controlling, inhibition of PI3K/Akt is necessary. Furthermore, the release of cytokines and the activation of inflammasomes contribute to the enhancement of vascular permeability, which results in edema within the myocardium. The immune response and inflammation represent the primary triggers in this process. The ability to control immune response and inflammation reactions may lead to the development of new therapies for microembolization.

1 January 2014 in World Chinese Journal of Digestology
Verified
Journal Article
Closed access
HLHui-Zhi Lu
Hui-Zhi Lu
LXLiang Xu
Liang Xu